.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Daurismo for Newly Diagnosed AML

February 13, 2019

Drew Boxler

Daurismo (glasdegib, Pfizer)

Indications: Newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older and have comorbidities that preclude use of intensive induction chemotherapy

Dosage: 100 mg orally, once daily.

Contraindications: None

Click here for more prescribing information